Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019-2026 UPDATE AVAILABLE ON-DEMAND Forecast up to 2027
The psoriatic arthritis treatment market refers to the market for products and therapies used in the management and treatment of psoriatic arthritis (PsA). PsA is a chronic inflammatory arthritis that affects individuals with psoriasis, a skin condition characterized by red, scaly patches on the skin. PsA can cause joint pain, stiffness, swelling, and progressive joint damage if left untreated. There has been an improved understanding of psoriatic arthritis among patients, healthcare professionals, and the general population. Increased awareness campaigns, educational initiatives, and advancements in diagnostic techniques have led to early detection and diagnosis of psoriatic arthritis. This has resulted in a higher demand for effective treatment options, driving the market growth. On the contrary, huge cost of treatment and dearth of standardization tools for diagnosis are likely to hamper the psoriatic arthritis treatment market growth. The Psoriatic Arthritis Treatment Market is likely to grow at a rate of 7.8% CAGR by 2027.
Psoriatic Arthritis Treatment Market By Drug Type
NSAIDs
DMARDs
Biologics
Psoriatic Arthritis Treatment Market By Type
Prescription
OTC
Psoriatic Arthritis Treatment Market By Route of Administration
Injectable
Oral
Topical
Psoriatic Arthritis Treatment Market By Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the psoriatic arthritis treatment market:
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs are commonly used as first-line treatment for PsA to manage pain, inflammation, and stiffness. These medications help reduce symptoms and improve joint function. Over-the-counter NSAIDs like ibuprofen and naproxen, as well as prescription-strength options, are available.
Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs are used to slow down the progression of joint damage in PsA and reduce inflammation. Traditional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, may be prescribed. Additionally, targeted synthetic DMARDs like apremilast and Janus kinase (JAK) inhibitors such as tofacitinib and baricitinib have shown efficacy in psoriatic arthritis treatment.
Biologic Therapies: Biologic drugs are a class of medications that target specific molecules involved in the immune response. Biologics, including tumor necrosis factor (TNF) inhibitors (e.g., etanercept, adalimumab), interleukin (IL)-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., ustekinumab, guselkumab), have revolutionized PsA treatment. These drugs are typically administered by injection or infusion and are used when other treatments have been inadequate.
Corticosteroids: Corticosteroids, such as prednisone, may be used to provide short-term relief from inflammation and pain in psoriatic arthritis. They are usually administered orally or through injections directly into the affected joints. However, long-term use of corticosteroids is generally avoided due to the potential for side effects.
Physical Therapy and Exercise: Physical therapy plays a crucial role in managing PsA. It helps improve joint mobility, strengthen muscles, and reduce pain. Exercises, such as range-of-motion exercises and low-impact activities like swimming and cycling, can also be beneficial for maintaining joint function and overall well-being.
Market Trends: The psoriatic arthritis treatment market is witnessing several trends. There is a growing emphasis on personalized medicine, with healthcare providers tailoring treatment plans to individual patients based on disease severity, comorbidities, and patient preferences. Additionally, the development of novel biologics and targeted therapies, as well as research exploring the use of combination therapies, is expanding the treatment options available for psoriatic arthritis. In addition, there is an increasing emphasis on patient-centric approaches in the management of psoriatic arthritis which is also a key trend observed in the market.
The major leading companies of the psoriatic arthritis treatment market are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company., Johnson & Johnson., Merck & Co Inc., Mylan N.V, Novartis AG, Pfizer Inc., and UCB S.A.
It is important for individuals with PsA to work closely with healthcare professionals to develop a comprehensive treatment plan that may include a combination of medications, lifestyle modifications, and supportive therapies. Regular monitoring and follow-up are essential to ensure the ongoing management and optimization of treatment for psoriatic arthritis.
An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the psoriatic arthritis treatment market in the forecast period.
An exact estimation of the psoriatic arthritis treatment market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
Psoriatic Arthritis Treatment Market By Drug Type
NSAIDs
DMARDs
Biologics
Psoriatic Arthritis Treatment Market By Type
Prescription
OTC
Psoriatic Arthritis Treatment Market By Route of Administration
Injectable
Oral
Topical
Psoriatic Arthritis Treatment Market By Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the psoriatic arthritis treatment market:
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs are commonly used as first-line treatment for PsA to manage pain, inflammation, and stiffness. These medications help reduce symptoms and improve joint function. Over-the-counter NSAIDs like ibuprofen and naproxen, as well as prescription-strength options, are available.
Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs are used to slow down the progression of joint damage in PsA and reduce inflammation. Traditional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, may be prescribed. Additionally, targeted synthetic DMARDs like apremilast and Janus kinase (JAK) inhibitors such as tofacitinib and baricitinib have shown efficacy in psoriatic arthritis treatment.
Biologic Therapies: Biologic drugs are a class of medications that target specific molecules involved in the immune response. Biologics, including tumor necrosis factor (TNF) inhibitors (e.g., etanercept, adalimumab), interleukin (IL)-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., ustekinumab, guselkumab), have revolutionized PsA treatment. These drugs are typically administered by injection or infusion and are used when other treatments have been inadequate.
Corticosteroids: Corticosteroids, such as prednisone, may be used to provide short-term relief from inflammation and pain in psoriatic arthritis. They are usually administered orally or through injections directly into the affected joints. However, long-term use of corticosteroids is generally avoided due to the potential for side effects.
Physical Therapy and Exercise: Physical therapy plays a crucial role in managing PsA. It helps improve joint mobility, strengthen muscles, and reduce pain. Exercises, such as range-of-motion exercises and low-impact activities like swimming and cycling, can also be beneficial for maintaining joint function and overall well-being.
Market Trends: The psoriatic arthritis treatment market is witnessing several trends. There is a growing emphasis on personalized medicine, with healthcare providers tailoring treatment plans to individual patients based on disease severity, comorbidities, and patient preferences. Additionally, the development of novel biologics and targeted therapies, as well as research exploring the use of combination therapies, is expanding the treatment options available for psoriatic arthritis. In addition, there is an increasing emphasis on patient-centric approaches in the management of psoriatic arthritis which is also a key trend observed in the market.
The major leading companies of the psoriatic arthritis treatment market are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company., Johnson & Johnson., Merck & Co Inc., Mylan N.V, Novartis AG, Pfizer Inc., and UCB S.A.
It is important for individuals with PsA to work closely with healthcare professionals to develop a comprehensive treatment plan that may include a combination of medications, lifestyle modifications, and supportive therapies. Regular monitoring and follow-up are essential to ensure the ongoing management and optimization of treatment for psoriatic arthritis.
An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the psoriatic arthritis treatment market in the forecast period.
An exact estimation of the psoriatic arthritis treatment market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. NSAIDs
5.3. DMARDs
5.4. Biologics
6. TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Prescription
6.3. OTC
7. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Injectable
7.3. Oral
7.4. Topical
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Amgen Inc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bristol-Myers Squibb Company
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Eli Lilly And Company
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Johnson & Johnson
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Merck & Co Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Mylan N.V
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Novartis AG
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. UCB S.A
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. NSAIDs
5.3. DMARDs
5.4. Biologics
6. TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Prescription
6.3. OTC
7. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Injectable
7.3. Oral
7.4. Topical
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Amgen Inc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bristol-Myers Squibb Company
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Eli Lilly And Company
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Johnson & Johnson
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Merck & Co Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Mylan N.V
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Novartis AG
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. UCB S.A
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR NSAIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR DMARDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR BIOLOGICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR PRESCRIPTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR OTC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR TOPICAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 17. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 20. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 24. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 27. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 30. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 33. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 36. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 39. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 42. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 49. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 52. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 55. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. ABBVIE INC.: FINANCIALS
TABLE 64. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 65. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 66. AMGEN INC.: FINANCIALS
TABLE 67. AMGEN INC.: PRODUCTS & SERVICES
TABLE 68. AMGEN INC.: RECENT DEVELOPMENTS
TABLE 69. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 70. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 71. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 72. ELI LILLY AND COMPANY: FINANCIALS
TABLE 73. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 74. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 75. JOHNSON & JOHNSON: FINANCIALS
TABLE 76. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 77. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 78. MERCK & CO INC.: FINANCIALS
TABLE 79. MERCK & CO INC.: PRODUCTS & SERVICES
TABLE 80. MERCK & CO INC.: RECENT DEVELOPMENTS
TABLE 81. MYLAN N.V: FINANCIALS
TABLE 82. MYLAN N.V: PRODUCTS & SERVICES
TABLE 83. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 84. NOVARTIS AG: FINANCIALS
TABLE 85. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 86. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 87. PFIZER INC.: FINANCIALS
TABLE 88. PFIZER INC.: PRODUCTS & SERVICES
TABLE 89. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 90. UCB S.A: FINANCIALS
TABLE 91. UCB S.A: PRODUCTS & SERVICES
TABLE 92. UCB S.A: RECENT DEVELOPMENTS
TABLE 1. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR NSAIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR DMARDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR BIOLOGICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR PRESCRIPTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR OTC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET VALUE FOR TOPICAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 17. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 20. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 24. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 27. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 30. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 33. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 36. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 39. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 42. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 49. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 52. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 55. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. ABBVIE INC.: FINANCIALS
TABLE 64. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 65. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 66. AMGEN INC.: FINANCIALS
TABLE 67. AMGEN INC.: PRODUCTS & SERVICES
TABLE 68. AMGEN INC.: RECENT DEVELOPMENTS
TABLE 69. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 70. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 71. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 72. ELI LILLY AND COMPANY: FINANCIALS
TABLE 73. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 74. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 75. JOHNSON & JOHNSON: FINANCIALS
TABLE 76. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 77. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 78. MERCK & CO INC.: FINANCIALS
TABLE 79. MERCK & CO INC.: PRODUCTS & SERVICES
TABLE 80. MERCK & CO INC.: RECENT DEVELOPMENTS
TABLE 81. MYLAN N.V: FINANCIALS
TABLE 82. MYLAN N.V: PRODUCTS & SERVICES
TABLE 83. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 84. NOVARTIS AG: FINANCIALS
TABLE 85. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 86. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 87. PFIZER INC.: FINANCIALS
TABLE 88. PFIZER INC.: PRODUCTS & SERVICES
TABLE 89. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 90. UCB S.A: FINANCIALS
TABLE 91. UCB S.A: PRODUCTS & SERVICES
TABLE 92. UCB S.A: RECENT DEVELOPMENTS
